All In MedTech

FDA Clearance Tracker · P120023-S005

KAMRA INLAY

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 18, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 18, 2017

Approved

Time to decision

174 days

Received Jan 25, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P120023-S005
Device name
KAMRA INLAY
Applicant
Corneagen
Applicant location
Seattle, WA
Received
Jan 25, 2017
Decided
Jul 18, 2017
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P120023

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code LQE

FDA's approval statement

As written in FDA's record.

Approval for revisions to the labeling to include the results of the post-approval study.

Source documents

Other decisions for Corneagen

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.